Cargando…
Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study
BACKGROUND: Intravenous infusion of ketamine can produce rapid and large symptom reduction in patients with treatment-resistant depression (TRD) but presents major obstacles to clinical applicability, especially in community settings. Oral esketamine may be a promising addition to our TRD treatment...
Autores principales: | Smith-Apeldoorn, Sanne Y., Veraart, Jolien K. E., Ruhé, Henricus G., aan het Rot, Marije, Kamphuis, Jeanine, de Boer, Marrit K., Schoevers, Robert A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693908/ https://www.ncbi.nlm.nih.gov/pubmed/34865676 http://dx.doi.org/10.1192/bjo.2021.1059 |
Ejemplares similares
-
The antidepressant effect and safety of non-intranasal esketamine: A systematic review
por: Smith-Apeldoorn, Sanne Y, et al.
Publicado: (2022) -
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
por: Smith-Apeldoorn, Sanne Y., et al.
Publicado: (2019) -
Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
por: Smith-Apeldoorn, Sanne Y., et al.
Publicado: (2020) -
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
por: Breeksema, Joost J., et al.
Publicado: (2023) -
The Effects of Tryptophan on Everyday Interpersonal Encounters and Social Cognitions in Individuals with a Family History of Depression
por: Hogenelst, Koen, et al.
Publicado: (2015)